Evidence map›Paper›PMID 38517220›Full record

ArticleHuman vaccines & immunotherapeutics2024

Impact of COVID-19 vaccination status on hospitalization and disease severity: A descriptive study in Nagasaki Prefecture, Japan.

Guoxi Cai, Shiwen Liu, Yixiao Lu, Yumika Takaki, Fumiaki Matsumoto, Akira Yoshikawa, Toshitsugu Taguri, Jianfen Xie, Kazuhiko Arima, Satoshi Mizukami and 9 more

Abstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Guoxi CaiPublic Health and Hygiene Research Department, Nagasaki Prefectural Institute of Environment and Public Health, Nagasaki, Japan.
Shiwen LiuDepartment of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, 1 Xuefu North Road, Fuzhou, Fujian Province, China.
Yixiao LuDepartment of Systems Biology and Health Statistics, School of Public Health (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Shenzhen, Guangdong, China.
Yumika TakakiPublic Health and Hygiene Research Department, Nagasaki Prefectural Institute of Environment and Public Health, Nagasaki, Japan.
Fumiaki MatsumotoPublic Health and Hygiene Research Department, Nagasaki Prefectural Institute of Environment and Public Health, Nagasaki, Japan.
Akira YoshikawaPublic Health and Hygiene Research Department, Nagasaki Prefectural Institute of Environment and Public Health, Nagasaki, Japan.
Toshitsugu TaguriPublic Health and Hygiene Research Department, Nagasaki Prefectural Institute of Environment and Public Health, Nagasaki, Japan.
Jianfen XieFujian Provincial Center for Disease Control and Prevention, Fuzhou, Fujian Province, China.
Kazuhiko ArimaDepartment of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Satoshi MizukamiDepartment of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Jiwen WuDepartment of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Taro YamamotoDepartment of International Health and Medical Anthropology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan.
Maiko HasegawaInfectious Disease Control Office, Health & Welfare Department, Nagasaki Prefectural Government, Nagasaki, Japan.
Nguyen Tien HuyInstitute of Research and Development, Duy Tan University, Da Nang, Vietnam.
Masaya SaitoDepartment of Nutrition Science, Faculty of Nursing and Nutrition, University of Nagasaki, Nagasaki, Japan.
Shouhei TakeuchiDepartment of Nutrition Science, Faculty of Nursing and Nutrition, University of Nagasaki, Nagasaki, Japan.
Kouichi MoritaDepartment of Virology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan.
Kiyoshi AoyagiDepartment of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Fei HeDepartment of Epidemiology and Health Statistics, School of Public Health, Fujian Medical University, 1 Xuefu North Road, Fuzhou, Fujian Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Coronavirus disease 2019 (COVID-19) was extraordinarily harmful, with high rates of infection and hospitalization. This study aimed to evaluate the impact of COVID-19 vaccination status and other factors on hospitalization and disease severity, using data from Nagasaki Prefecture, Japan. Confirmed cases of COVID-19 infection with vaccination status were included and the differences in characteristics between different vaccination statuses, hospitalization or not, and patients with varying levels of disease severity were analyzed. Furthermore, logistic regression was used to calculate odds ratio (ORs) and 95% confidence intervals (CI) to evaluate the association of various factors with hospitalization and disease severity. From March 14, 2020 to August 31, 2022, 23,139 patients were unvaccinated 13,668 vaccinated the primary program with one or two doses, and 4,575 completed the booster. Vaccination reduced the risk of hospitalization with an odd ratio of 0.759 (95% CI: 0.654-0.881) and the protective effect of completed booster vaccination was more pronounced (OR: 0.261, 95% CI: 0.207-0.328). Similarly, vaccination significantly reduced the risk of disease severity (vaccinated primary program: OR: 0.191, 95% CI: 0.160-0.228; completed booster vaccination: OR: 0.129, 95% CI: 0.099-0.169). Overall, unvaccinated, male, elderly, immunocompromised, obese, and patients with other severe illness factors were all risk factors for COVID-19-related hospitalization and disease severity. Vaccination was associated with a decreased risk of hospitalization and disease severity, and highlighted the benefits of completing booster.

Indexed as

COVID-19AgedCOVID-19 VaccinesHospitalizationHumansJapanMalePatient AcuityVaccinationCOVID-19 VaccinesCOVID-19hospitalizationJapanmRNA vaccinevaccination

Identifiers

PMID38517220
PMCPMC10962621

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.